Screener

Eligibility screening

Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Sponsored by Revolution Medicines, Inc.Study detailsClinicalTrials.gov

2 US sites in NV, OH

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.